Genes to GMP: Biocatalysis in the pharmaceutical industry today

Biocatalysis is no longer considered an emerging technology in the pharmaceutical industry; it has taken a firm foothold in the form of numerous manufacturing processes, with applications ranging from pre-clinical development batches to commercial API manufacture. The rise of biocatalysis is inextricably linked to the ease of access to the enzymes it relies on.

Stefan Mix of Almac Group looks at how a once niche technology has gone mainstream.